Prous Institute is launching a business model based on its drug discovery activities and proprietary technology to build partnerships and collaborations with industry, public health organizations and academia. The Institute is in close collaboration with a network of academic scientists to validate the predictions of the in silico models.
Food & Drug Administration (FDA), USA
Under the Material Transfer Agreement (MTA), the Informatics and Computational Safety Analysis Staff (ICSAS) of the US FDA Center for Drug Evaluation and Research (FDA/CDER) is evaluating
BioEpisteme® as part of its computational toxicology program, the goal of which is to use in silico software to predict all toxicological endpoints and adverse clinical effects of chemicals of interest to the US FDA. Our objective in this ongoing collaboration with ICSAS is to form an eventual Cooperative Research and Development Agreement (CRADA) which in turn will lead to the development of FDA QSAR toxicity models for
BioEpisteme® that will allow scientists to anticipate potential toxicity and adverse human clinical effects of pharmaceuticals and other chemicals.
Prous Institute Encourages Collaborative Research